Evidence map›Paper›PMID 35392217›Full record

ReviewFrontiers in oncology2022

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.

Lele Miao, Juan Zhang, Binjie Huang, Zhengchao Zhang, Song Wang, Futian Tang, Muzhou Teng, Yumin Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Engineering resilient CAR T cells for immunosuppressive environment.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lele MiaoDepartment of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.
Juan ZhangDepartment of Hematology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Binjie HuangDepartment of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.
Zhengchao ZhangDepartment of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.
Song WangDepartment of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.
Futian TangKey Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou, China.
Muzhou TengKey Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou, China.
Yumin LiDepartment of General Surgery, Second Hospital of Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) -T cell therapy has become one of the hot topics in tumor immunity research in recent years. Although CAR-T cell therapy is highly effective in treating hematological malignancies, there are numerous obstacles that prevent CAR-T cells from having anti-tumor effects. Traditional CARs, from the first to the fourth generation, are incapable of completely overcoming these challenges. Therefore, identifying ways to boost the efficacy of CAR-T cells by utilizing the limited tumor surface antigens has become an urgent area of research. Certain special CARs that have special structures, special systems, or are greatly improved on the basis of traditional CARs, such as tandem CAR, dual-signaling CARs, AND-gate CARs, inhibitory CAR, AND-NOT CARs, CARs with three scFvs, ON/OFF-switch CARs, and universal CARs have been introduced. This study aims to use these special CARs to improve the anti-tumor ability, accuracy, and safety of CAR-T cells. In addition to summarizing various special CARs of T cells, this paper also expounds some of our own conjectures, aiming to provide reference and inspiration for CARs researchers.

Indexed as

conjecturesefficacyimprovesafetyspecial CARs

Identifiers

PMID35392217
PMCPMC8981721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.